Overview
Entos is a pioneer in the 'TechBio' sector, leveraging its proprietary OrbNet technology to bridge the gap between high-fidelity quantum mechanics and the speed of machine learning. Unlike traditional drug discovery platforms that rely on heuristic-based models, Entos utilizes physics-informed AI architecture to predict molecular properties with the accuracy of Density Functional Theory (DFT) but at 1,000x to 10,000x the speed. This allows for the screening of billions of compounds in a fraction of the time. By 2026, Entos has positioned itself as the backbone of hybrid therapeutic pipelines, integrating its EnSieve high-throughput screening with active learning loops that refine lead candidates in real-time. The platform is designed for medicinal chemists and computational biologists who require high-confidence predictions for ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiles before physical synthesis. Its architecture is built to handle massive datasets while maintaining thermodynamic consistency, making it a critical tool for tackling 'undruggable' targets and optimizing lead compounds in the hit-to-lead phase of pharmaceutical R&D.